Key points – Ibrutinib demonstrates durable responses and sustained single-agent activity in relapsed or refractory MCL at median 26.7-month follow-up. Ibrutinib shows a favorable benefit-risk profile over time, with a manageable safety profile.
Home / Resource Library / Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results